From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot
Taisir Bozo1, Annette Murr2, Birte Holtfreter1
1Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Greifswald, Germany.
Introduction:
This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug-target database screening.
Methods:
Proteomic analyses of saliva using LC-MS/MS were conducted in two independent settings: a cohort (sub-study I, N = 187) and case-control (sub-study II, N = 72). Statistical analyses were performed using both stringent and lenient criteria. Under the stringent (lenient) criteria, proteins were considered potential targets if they showed a q-value < 0.05 (< 0.1) in the cohort study and a p-value < 0.05 together with an absolute fold change > 1.5 (1.3) in the case-control study. Four databases were searched to assess whether these proteins are known targets of approved drugs.
Results:
In the stringent (lenient) analysis one (26) proteins were associated with periodontitis in both studies, of which one (nine) were reported drug targets and one (seven) of those were potential drug targets in periodontitis. Target screening in databases identified 3/11 approved drugs, with eight of them having potential for repurposing for periodontal treatment. Several of these drugs (e.g., HDAC inhibitors, sivelestat, compstatin derivatives, auranofin, artenimol and bortezomib) have already shown efficacy in preclinical models of periodontal host modulation.
Conclusion:
This exploratory pilot study provided insights into potential therapeutic targets and potential drugs for periodontitis treatment. This workflow may help to identify approved drugs that could be repurposed for periodontal treatment.
